Analyse BillionToOne, Inc. (BLLN) — Kairos Score 67/100

À propos de BillionToOne, Inc.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Informations clés

🕴️ Activité des initiés (90 jours)

50 transactions — 0 achats et 62 ventes déclarés par les dirigeants de BillionToOne, Inc..

🏦 Hedge Funds

20 fonds institutionnels déclarent une position sur BLLN dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur BLLN.

• BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
• BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

🔎 Intérêt de recherche Google

0/100 — intérêt actuel

Volume de recherche Google pour "BLLN" sur 90 jours (échelle 0-100, 100 = pic de la période). Moyenne 90j : 0.6/100, pic max : 9/100.

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.